Sei Investments Co. Acquires Shares of 56,854 Avalo Therapeutics, Inc. $AVTX

Sei Investments Co. purchased a new stake in shares of Avalo Therapeutics, Inc. (NASDAQ:AVTX) in the first quarter, according to the company in its most recent filing with the SEC. The fund purchased 56,854 shares of the company’s stock, valued at approximately $849,000.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Dimensional Fund Advisors LP bought a new stake in shares of Avalo Therapeutics in the 3rd quarter worth $143,000. Boothbay Fund Management LLC bought a new position in shares of Avalo Therapeutics during the second quarter valued at about $56,000. AlphaCentric Advisors LLC bought a new position in shares of Avalo Therapeutics during the first quarter valued at about $174,000. Jump Financial LLC purchased a new position in Avalo Therapeutics during the fourth quarter worth about $238,000. Finally, Persistent Asset Partners Ltd purchased a new position in Avalo Therapeutics during the fourth quarter worth about $274,000. 87.06% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

AVTX has been the subject of a number of research analyst reports. Weiss Ratings raised Avalo Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Tuesday. Cantor Fitzgerald reissued an “overweight” rating on shares of Avalo Therapeutics in a research report on Friday, July 24th. BTIG Research restated a “buy” rating and issued a $58.00 price objective on shares of Avalo Therapeutics in a research note on Tuesday, June 16th. Piper Sandler reaffirmed an “overweight” rating and set a $60.00 target price (up from $48.00) on shares of Avalo Therapeutics in a research report on Monday, May 11th. Finally, Mizuho lifted their target price on Avalo Therapeutics from $39.00 to $45.00 and gave the stock an “outperform” rating in a research note on Thursday, May 14th. Thirteen research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $45.10.

Avalo Therapeutics Trading Down 0.5%

Shares of Avalo Therapeutics stock opened at $19.45 on Friday. The company’s 50-day moving average price is $17.69 and its 200-day moving average price is $16.41. Avalo Therapeutics, Inc. has a 12-month low of $8.41 and a 12-month high of $24.27. The company has a market cap of $1.04 billion, a price-to-earnings ratio of -4.45 and a beta of 0.80.

Avalo Therapeutics (NASDAQ:AVTX) last posted its earnings results on Thursday, August 6th. The company reported ($0.83) EPS for the quarter, missing the consensus estimate of ($0.58) by ($0.25). On average, sell-side analysts predict that Avalo Therapeutics, Inc. will post -2.59 earnings per share for the current year.

Insider Buying and Selling at Avalo Therapeutics

In other Avalo Therapeutics news, insider Mittie Doyle sold 1,450 shares of Avalo Therapeutics stock in a transaction that occurred on Tuesday, June 23rd. The shares were sold at an average price of $18.00, for a total transaction of $26,100.00. Following the transaction, the insider directly owned 51,776 shares of the company’s stock, valued at approximately $931,968. This trade represents a 2.72% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Corporate insiders own 4.46% of the company’s stock.

About Avalo Therapeutics

Avalo Therapeutics is a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for cardiometabolic, fibrotic and inflammatory diseases. The company’s proprietary drug-design platform enables the creation of long-acting prodrugs with optimized pharmacokinetic profiles, aiming to improve efficacy, safety and patient adherence. By leveraging this technology, Avalo seeks to address key drivers of disease progression that remain underserved by existing treatments.

Its lead programs include AVTX-002, a first-in-class prodrug candidate designed to inhibit angiotensinogen for the treatment of hypertension and related cardiovascular disorders, and AVTX-006, an early-stage candidate targeting pathways implicated in fibrosis and metabolic dysfunction.